Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 20/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12795589 | 0.93 | P2RX7 (0.72) | P2RX7 | |
| SCHEMBL12795576 | 0.91 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL12795620 | 0.90 | P2RX7 (0.71) | P2RX7 | |
| SCHEMBL12795587 | 0.88 | P2RX7 (0.83) | P2RX7 | |
| SCHEMBL14225125 | 0.86 | P2RX7 (0.82) | P2RX7 | |
| SCHEMBL13985060 | 0.85 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL12795581 | 0.84 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL14225127 | 0.84 | P2RX7 (0.87) | P2RX7 | |
| SCHEMBL12795652 | 0.84 | P2RX7 (0.94) | P2RX7 | |
| SCHEMBL12795605 | 0.83 | P2RX7 (0.89) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349858-B2 | Polycyclic guanine derivatives and use thereof | MERCK SHARP & DOHME (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349858-B2 | Polycyclic guanine derivatives and use thereof | MERCK SHARP & DOHME (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120316176-A1 | DERIVATIVES OF 7,8-DIHYDRO-1H-IMIDAZO[2,1-b] PURIN-4(5H)-ONE and METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2012-12-13 | — | — | US | disclosed |
| US-20120316176-A1 | DERIVATIVES OF 7,8-DIHYDRO-1H-IMIDAZO[2,1-b] PURIN-4(5H)-ONE and METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2012-12-13 | — | — | US | disclosed |
| US-20110065738-A1 | POLYCYCLIC GUANINE DERIVATIVES AND USE THEREOF | SCHERING CORPORATION | 2011-03-17 | — | — | US | disclosed |
| US-20110065738-A1 | POLYCYCLIC GUANINE DERIVATIVES AND USE THEREOF | SCHERING CORPORATION | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316176-A1 | DERIVATIVES OF 7,8-DIHYDRO-1H-IMIDAZO[2,1-b] PURIN-4(5H)-ONE and METHODS OF USE THEREOF | P2RX7, P2RX4, P2RX3 | P2RX7 1/4885 |
| US-20110065738-A1 | POLYCYCLIC GUANINE DERIVATIVES AND USE THEREOF | GDA, HPRT1, GMPS | P2RX7 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.